康柏西普联合全视网膜光凝治疗进展型糖尿病性视网膜病变的临床疗效评价  

Clinical Efficacy of Conbercept Combined with Panretinal Photocoagulation in the Treatment of Progressive Diabetic Retinopathy

作　　者：王勇 王景 安明[3] WANG Yong;WANG Jing;AN Ming(Qingdao Ludong Ophthalmological Hospital,Qingdao,Shandong,China 266000;Qingdao Fubo Ophthalmological Hospital,Qingdao,Shandong,China 266000;Department of Ophthalmology,Qingdao Municipal Hospital,Qingdao,Shandong,China 266000)

机构地区：[1]青岛鲁东眼科医院,山东青岛266000 [2]青岛福柏眼科医院,山东青岛266000 [3]山东省青岛市市立医院眼科,山东青岛266000

出　　处：《中国药业》2019年第19期46-48,共3页China Pharmaceuticals

基　　金：2015年度山东省科技发展计划项目[2015GGX102053]

摘　　要：目的探讨康柏西普联合全视网膜光凝(PRP)治疗进展型糖尿病性视网膜病变(DR)的临床疗效。方法选择医院2016年5月至2017年5月收治的进展型DR患者120例,按随机数字表法分为观察组和对照组,各60例。两组均给予PRP术式治疗,观察组在PRP术式治疗前1周给予康柏西普球内注射治疗,均随访1个月。结果观察组总有效率为98.33%,优于对照组的88.33%(P<0.05);治疗后,两组患者的视神经纤维层(RNFL)厚度和黄斑厚度均低于治疗前,且观察组低于对照组(P<0.05);两组治疗后1周、2周及1个月的视力均明显高于治疗前,且观察组各时段均高于对照组(P<0.05);两组不良反应发生率相当(28.33%比33.33%,P>0.05)。结论康柏西普联合PRP治疗进展型DR的疗效较好,可有效改善患者的症状体征及视力,安全性较高。Objective To investigate the clinical efficacy of Conbercept combined with panretinal photocoagulation(PRP)in the treatment of progressive diabetic retinopathy(DR).Methods Totally 120 patients with progressive DR admitted to our hospital from May 2016 to May 2017 were selected and divided into the observation group and the control group according to the random number table method,60 cases in each group.The patients in the two groups were treated with PRP.The patients in the observation group were treated with Conbercept 1 week before giving intramuscular injection of TRP.All patients were followed up for 1 month.Results The total effective rate of the observation group was 98.33%,which was significantly better than 88.33%of the control group(P<0.05).After treatment,the thickness of retinal nerve fiber layer(RNFL)and macular in the two groups was thinner than that before treatment,and that in the observation group was thinner than that in the control group(P<0.05).1 week,2 weeks and 1 month after treatment,the scores of visual acuity in the two groups were significantly higher than those before treatment,and those in the observation group were higher than those in the control group(P<0.05).The incidence of adverse reactions was similar between the two groups(28.33%vs.33.33%,P>0.05).Conclusion Conbercept combined with PRP is effective and safety in the treatment of progressive DR,it can effectively improve the symptoms,signs and visual acuity of the patients.

关 键 词：康柏西普 全视网膜光凝 进展型 糖尿病性视网膜病变 临床疗效 

分 类 号：R969.4[医药卫生—药理学] R988.1[医药卫生—药学]